Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 254

1.

Nottingham trial of faecal occult blood testing for colorectal cancer: a 20-year follow-up.

Scholefield JH, Moss SM, Mangham CM, Whynes DK, Hardcastle JD.

Gut. 2012 Jul;61(7):1036-40. doi: 10.1136/gutjnl-2011-300774. Epub 2011 Nov 3.

PMID:
22052062
2.

Colorectal cancer, screening and survival: the influence of socio-economic deprivation.

Whynes DK, Frew EJ, Manghan CM, Scholefield JH, Hardcastle JD.

Public Health. 2003 Nov;117(6):389-95.

PMID:
14522153
3.

How often is a positive faecal occult blood test the result of coeliac disease?

Logan RF, Howarth GF, West J, Shepherd K, Robinson MH, Hardcastle JD.

Eur J Gastroenterol Hepatol. 2003 Oct;15(10):1097-100.

PMID:
14501618
4.

Asymptomatic colorectal neoplasia and fecal characteristics: a case-control study of subjects participating in the nottingham fecal occult blood screening trial.

Little J, Owen RW, Fernandez F, Hawtin PG, Hill MJ, Logan RF, Thompson MH, Hardcastle JD.

Dis Colon Rectum. 2002 Sep;45(9):1233-41.

PMID:
12352242
5.
6.

Psychiatric morbidity and screening for colorectal cancer.

Parker MA, Robinson MH, Scholefield JH, Hardcastle JD.

J Med Screen. 2002;9(1):7-10.

PMID:
11943790
7.

High prevalence of undetected ulcerative colitis: data from the Nottingham fecal occult blood screening trial.

Howarth GF, Robinson MH, Jenkins D, Hardcastle JD, Logan RF.

Am J Gastroenterol. 2002 Mar;97(3):690-4.

PMID:
11926210
8.

Randomized double-blind phase II survival study comparing immunization with the anti-idiotypic monoclonal antibody 105AD7 against placebo in advanced colorectal cancer.

Maxwell-Armstrong CA, Durrant LG, Buckley TJ, Scholefield JH, Robins RA, Fielding K, Monson JR, Guillou P, Calvert H, Carmichael J, Hardcastle JD.

Br J Cancer. 2001 Jun 1;84(11):1443-6.

9.

Faecal occult blood screening for colorectal cancer at Nottingham: details of the verification process.

Robinson MH, Rodrigues VC, Hardcastle JD, Chamberlain JO, Mangham CM, Moss SM.

J Med Screen. 2000;7(2):97-8.

PMID:
11002450
10.

A prospective multicenter evaluation of new fecal occult blood tests in patients undergoing colonoscopy.

Greenberg PD, Bertario L, Gnauck R, Kronborg O, Hardcastle JD, Epstein MS, Sadowski D, Sudduth R, Zuckerman GR, Rockey DC.

Am J Gastroenterol. 2000 May;95(5):1331-8.

PMID:
10811348
11.

Antibodies raised by gastrimmune inhibit the spontaneous metastasis of a human colorectal tumour, AP5LV.

Watson SA, Michaeli D, Morris TM, Clarke P, Varro A, Griffin N, Smith A, Justin T, Hardcastle JD.

Eur J Cancer. 1999 Aug;35(8):1286-91.

PMID:
10615243
12.

Survival of patients with colorectal cancer diagnosed in a randomized controlled trial of faecal occult blood screening.

Mapp TJ, Hardcastle JD, Moss SM, Robinson MH.

Br J Surg. 1999 Oct;86(10):1286-91.

PMID:
10540135
13.

Increased activation of lymphocytes infiltrating primary colorectal cancers following immunisation with the anti-idiotypic monoclonal antibody 105AD7.

Maxwell-Armstrong CA, Durrant LG, Robins RA, Galvin AM, Scholefield JH, Hardcastle JD.

Gut. 1999 Oct;45(4):593-8.

14.

The risks of screening: data from the Nottingham randomised controlled trial of faecal occult blood screening for colorectal cancer.

Robinson MH, Hardcastle JD, Moss SM, Amar SS, Chamberlain JO, Armitage NC, Scholefield JH, Mangham CM.

Gut. 1999 Oct;45(4):588-92.

15.

Interval cancers in a randomized controlled trial of screening for colorectal cancer using a faecal occult blood test.

Moss SM, Hardcastle JD, Coleman DA, Robinson MH, Rodrigues VC.

Int J Epidemiol. 1999 Jun;28(3):386-90.

PMID:
10405838
16.

Direct mucosal targeting of colonic receptors by prokinetic drugs in an experimental model.

Ho YH, Evans DF, Hardcastle JD.

Ann Acad Med Singapore. 1999 Jan;28(1):31-6.

PMID:
10374023
17.

Should we be screening for colorectal cancer?

Robinson MH, Hardcastle JD.

Br Med Bull. 1998;54(4):807-21. Review.

PMID:
10367416
18.

A comparison of an anti-gastrin antibody and cytotoxic drugs in the therapy of human gastric ascites in SCID mice.

Watson SA, Michaeli D, Grimes S, Morris TM, Varro A, Clarke PA, Smith AM, Justin TA, Hardcastle JD.

Int J Cancer. 1999 Apr 12;81(2):248-54.

19.

Gastric carcinoid expresses the gastrin autocrine pathway.

Smith AM, Watson SA, Caplin M, Clarke P, Griffin N, Varro A, Hardcastle JD.

Br J Surg. 1998 Sep;85(9):1285-9.

PMID:
9752879
20.

Expression of CCKB/gastrin receptor isoforms in gastro-intestinal tumour cells.

Watson SA, Clarke PA, Smith AM, Varro A, Michaeli D, Grimes S, Caplin M, Hardcastle JD.

Int J Cancer. 1998 Aug 12;77(4):572-7.

21.

Screening for colorectal cancer reduces emergency admissions.

Scholefield JH, Robinson MH, Mangham CM, Hardcastle JD.

Eur J Surg Oncol. 1998 Feb;24(1):47-50.

PMID:
9542516
22.

Faecal occult blood screening for colorectal cancer: is it cost-effective?

Whynes DK, Neilson AR, Walker AR, Hardcastle JD.

Health Econ. 1998 Feb;7(1):21-9.

PMID:
9541081
23.

Pre-clinical evaluation of the Gastrimmune immunogen alone and in combination with 5-fluorouracil/leucovorin in a rat colorectal cancer model.

Watson SA, Michael D, Justin TA, Grimes S, Morris TM, Robinson G, Clarke PA, Hardcastle JD.

Int J Cancer. 1998 Mar 16;75(6):873-7.

24.

Endoscopic screening of relatives of patients with colorectal cancer.

Hunt LM, Rooney PS, Hardcastle JD, Armitage NC.

Gut. 1998 Jan;42(1):71-5.

25.
26.

The effect of onapristone, a progesterone antagonist, on the growth of human gastrointestinal cancer xenografts.

Jacobs E, Watson SA, Ellis IO, Hardcastle JD, Robertson JF.

Eur J Cancer. 1997 Jun;33(7):1130-5.

PMID:
9376194
27.

Long-term results of the Angelchik prosthesis for gastro-oesophageal reflux.

Maxwell-Armstrong CA, Steele RJ, Amar SS, Evans D, Morris DL, Foster GE, Hardcastle JD.

Br J Surg. 1997 Jun;84(6):862-4.

PMID:
9189111
28.

Colorectal cancer.

Hardcastle JD.

CA Cancer J Clin. 1997 Mar-Apr;47(2):66-9. No abstract available.

29.

Chemical and immunological testing for faecal occult blood in screening subjects at risk of familial colorectal cancer.

Hunt LM, Rooney PS, Bostock K, Robinson MH, Hardcastle JD, Armitage NC.

Gut. 1997 Jan;40(1):110-2.

30.

Oestrogen and progesterone receptors in gastrointestinal cancer cell lines.

Jacobs E, Watson SA, Hardcastle JD, Robertson JF.

Eur J Cancer. 1996 Dec;32A(13):2348-53.

PMID:
9038620
31.

Ki-ras mutations in adenomas: a characteristic of cancer-bearing colorectal mucosa.

Morris RG, Curtis LJ, Romanowski P, Hardcastle JD, Jenkins DA, Robinson M, Wyllie AH, Bird CC.

J Pathol. 1996 Dec;180(4):357-63.

PMID:
9014854
32.

Randomised controlled trial of faecal-occult-blood screening for colorectal cancer.

Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, James PD, Mangham CM.

Lancet. 1996 Nov 30;348(9040):1472-7.

PMID:
8942775
33.

Greater frequency of K-ras Val-12 mutation in colorectal cancer as detected with sensitive methods.

Carpenter KM, Durrant LG, Morgan K, Bennett D, Hardcastle JD, Kalsheker NA.

Clin Chem. 1996 Jun;42(6 Pt 1):904-9.

34.

Screening high-risk groups for colorectal neoplasia.

Hardcastle JD, Justin TA.

Am J Gastroenterol. 1996 May;91(5):850-2. Review. No abstract available.

PMID:
8633571
35.

Screening for colorectal cancer with an immunological faecal occult blood test: 2-year follow-up.

Robinson MH, Marks CG, Farrands PA, Bostock K, Hardcastle JD.

Br J Surg. 1996 Apr;83(4):500-1.

PMID:
8665240
36.

Value of a weekly surgical x-ray meeting.

Charnley RM, Amar SS, Gregson RH, Steele RJ, Bourke JB, Hardcastle JD.

Br J Surg. 1996 Mar;83(3):394-5. No abstract available.

PMID:
8665204
37.

Gastrimmune raises antibodies that neutralize amidated and glycine-extended gastrin-17 and inhibit the growth of colon cancer.

Watson SA, Michaeli D, Grimes S, Morris TM, Robinson G, Varro A, Justin TA, Hardcastle JD.

Cancer Res. 1996 Feb 15;56(4):880-5.

38.

Serum thymidine kinase in colorectal neoplasia.

Thomas WM, Robertson JF, McKenna PG, O'Neill KL, Robinson MH, Hardcastle JD.

Eur J Surg Oncol. 1995 Dec;21(6):632-4.

PMID:
8631410
39.

Colonoscopy for all first-degree relatives of patients with colorectal cancer.

Hunt LM, Hardcastle JD, Armitage NC.

Br J Surg. 1995 Dec;82(12):1644. No abstract available.

PMID:
8548228
40.

Fecal alpha 1-antitrypsin detection of colorectal neoplasia. An evaluation using HemoQuant.

Moran A, Robinson M, Lawson N, Stanley J, Jones AF, Hardcastle JD.

Dig Dis Sci. 1995 Dec;40(12):2522-5.

PMID:
8536506
41.

Two phase III trials of tauromustine (TCNU) in advanced colorectal cancer.

Smyth JF, Hardcastle JD, Denton G, Alderson D, Grace RH, Mansi JL, Yosef HM, Nordle O, Lauri H, Wählby S.

Ann Oncol. 1995 Nov;6(9):948-9. No abstract available.

PMID:
8624301
42.

Alkaline gastro-oesophageal reflux: dual probe pH monitoring.

Iftikhar SY, Ledingham S, Evans DF, Yusuf SW, Steele RJ, Atkinson M, Hardcastle JD.

Gut. 1995 Oct;37(4):465-70.

43.

Effect of gastrointestinal hormones and synthetic analogues on the growth of pancreatic cancer.

Robertson JF, Watson SA, Hardcastle JD.

Int J Cancer. 1995 Sep 27;63(1):69-75.

PMID:
7558455
44.

Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models.

Watson SA, Morris TM, Robinson G, Crimmin MJ, Brown PD, Hardcastle JD.

Cancer Res. 1995 Aug 15;55(16):3629-33.

45.

Five-year prospective study of DNA tumor ploidy and colorectal cancer survival.

Chapman MA, Hardcastle JD, Armitage NC.

Cancer. 1995 Aug 1;76(3):383-7.

PMID:
8625117
46.

Is an immunological faecal occult blood test better than Haemoccult? A cost-benefit study.

Robinson MH, Marks CG, Farrands PA, Whynes DK, Bostock K, Hardcastle JD.

Eur J Surg Oncol. 1995 Jun;21(3):261-4.

PMID:
7781793
47.

Anti-gastrin antibodies raised by gastrimmune inhibit growth of the human colorectal tumour AP5.

Watson SA, Michaeli D, Grimes S, Morris TM, Crosbee D, Wilkinson M, Robinson G, Robertson JF, Steele RJ, Hardcastle JD.

Int J Cancer. 1995 Apr 10;61(2):233-40.

PMID:
7705954
48.

Faecal occult blood testing and colonoscopy in the surveillance of subjects at high risk of colorectal neoplasia.

Robinson MH, Kronborg O, Williams CB, Bostock K, Rooney PS, Hunt LM, Hardcastle JD.

Br J Surg. 1995 Mar;82(3):318-20.

PMID:
7795994
49.

The sensitivity of competitive hybridisation for the detection of mutant p53 alleles in a background of wild type.

Carpenter K, Morgan K, Durrant LG, Hardcastle JD, Kalsheker N.

Biochem Soc Trans. 1995 Feb;23(1):129S. No abstract available.

PMID:
7758692
50.

The effect of calcium supplements on rectal mucosal proliferation.

Armitage NC, Rooney PS, Gifford KA, Clarke PA, Hardcastle JD.

Br J Cancer. 1995 Jan;71(1):186-90.

Supplemental Content

Loading ...
Support Center